Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Increase in BP over the next few days. Varied from 179/80 to 212/80; Mild headache; Light-headed; racing heart; This is a spontaneous report from a contactable consumer (patient). A 70-years-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: FA7812), via an unspecified route of administration on 04Jun2021 at 14:16 (at the age of vaccination) as 1st single dose for COVID-19 immunisation. Patient medical history included refractory hypertension. Concomitant medication included hydralazine hydrochloride (HYPERPHEN, tablet, dose: 2 tablets, 20mg) taken for blood pressure (BP). On 04Jun2021, the patient felt lightheaded, mild headache and had a racing heart during the 30 minutes of recovery and patient took lunchtime dose of Hyperphen (2 tablets, 20mg). Hyperphen is one of 4 other BP tablets prescribed (concomitant medication). The patient BP continued to go up to 212/79, increase in bp over the next few days, varied from 179/80 to 212/80. Patient saw her GP (general physician) on Monday 07Jun2021 and GP increased Hyperphen to 3x3 times a day and had increased hypertension medications. It has now gone down considerably. On 04Jun2021, the patient underwent lab tests and procedures which included blood pressure as 179/80 and on an unspecified date in Jun2021, BP was 212/80, and 212/79. Patient received treatment Hyperphen to 3x3 times a day and had increased hypertension medications for event increased BP. Patient informed to note the effect of the Pfizer vaccine on blood pressure. The outcome of event light-headed and racing heart was resolved on an unspecified date in 2021 and rest all events was resolving. No follow-up attempts are needed. No further information is expected.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166